Atlas Trials

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Clinical trial NCT05723432 · UNKNOWN

Trial details

NCT number
NCT05723432
Sponsor
Shanghai Kanda Biotechnology Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2023-03-22
Primary completion
2024-12-31
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.